Bangladesh’s Covid-19 vaccine “Bangavax” to start human trials soon.
“Globe Biotech” has now 3 Covid-19 vaccine candidates in WHO, its mRNA one named “Bangavax” finished animal’s trials with 95% success rate against 11 variants, including Delta.
NEWSBANGLADESH NEWS
“Globe Biotech” is working on three different types of Covid-19 vaccine, the more advanced is a mRNA-based named “Bangavax” (previously known as “Bancovid”), a DNA plasmid one, and an Adenovirus Type-5 vector.
Each of them was accepted in the draft landscape of the World Health Organization, the first time an organization has three Covid-19 candidates in WHO’s list.
Caution is naturally observed as there is no guarantee of success until the trials last phases, like several world leading pharmaceutical companies unfortunately experienced.
After testing in rats and rabbits, trial on monkeys were done during summer with a 95% success rate for 11 variants of Covid-19 including Delta, the company claims an expected variation of only 2% in human trials. The human trials are expected to start in the coming weeks, and we will keep you inform of its developments.
If the trials are successful, “Bangavax” will become the first effective single-dose vaccine based on mRNA technology. It can be preserved for one month at +4 degrees Celsius and six months at -20 degrees Celsius, and rumors put it at an attractive price.
The Nepalese company “Anmol Healthcare” will buy 2 million shots in this case, following a visit of “Globe Biotech” by the Nepalese ambassador, totaling 20 million doses in pre-order.
Whatever the outcome of “Bangavax”, successful or not, it nevertheless shows an increased level of sophistication of Bangladesh pharmaceutical industry, both in research and manufacturing capacity.
https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130517/
https://bdnews24.com/health/2021/05/06/bangavax-first-buzzed-with-hope-then-fizzled
https://thefinancialexpress.com.bd/national/pre-clinical-trials-of-bangavax-show-success-1634264874